Choroid plexus tumors; management, outcome, and association with the Li-Fraumeni syndrome: The Children's Hospital Los Angeles (CHLA) experience, 1991-2010

2011 ◽  
Vol 58 (6) ◽  
pp. 905-909 ◽  
Author(s):  
Alexa E. Gozali ◽  
Barbara Britt ◽  
Lisa Shane ◽  
Ignacio Gonzalez ◽  
Floyd Gilles ◽  
...  
Keyword(s):  
Los Angeles ◽  
Choroid Plexus ◽  
Choroid Plexus Tumors ◽  
Li Fraumeni Syndrome ◽  
Children's Hospital ◽  
Children’S Hospital ◽  
Li Fraumeni

scholarly journals Successful Treatment of Recurrent Li-Fraumeni Syndrome-related Choroid Plexus Carcinoma

2017 ◽  
Vol 39 (8) ◽  
pp. e473-e475 ◽  
Author(s):  
Matthew McEvoy ◽  
Nathan Robison ◽  
Peter Manley ◽  
Torunn Yock ◽  
Kristine Konopka ◽  
...  
Keyword(s):  
Choroid Plexus ◽  
Successful Treatment ◽  
Choroid Plexus Carcinoma ◽  
Li Fraumeni Syndrome ◽  
Li Fraumeni

Successful Treatment of an Unresectable Choroid Plexus Carcinoma in a Patient With Li-Fraumeni Syndrome

2005 ◽  
Vol 27 (1) ◽  
pp. 46-49 ◽  
Author(s):  
David S Dickens ◽  
Judith A Dothage ◽  
Richard L Heideman ◽  
Edgar T Ballard ◽  
Paul T Jubinsky
Keyword(s):  
Choroid Plexus ◽  
Successful Treatment ◽  
Choroid Plexus Carcinoma ◽  
Li Fraumeni Syndrome ◽  
Li Fraumeni

scholarly journals Mucin 4: A Sensitive Diagnostic Marker for Pediatric Mucoepidermoid CarcinomaNick Shillingford

2020 ◽  
pp. 1-12
Author(s):  
Mackenzie Postel M S ◽  
◽  
Julia T Chu ◽  
Henry H Tran ◽  
Shamlal Mangray ◽  
...  
Keyword(s):  
Los Angeles ◽  
Rhode Island ◽  
Predictive Value ◽  
Pediatric Population ◽  
Children's Hospital ◽  
Morphological Heterogeneity ◽  
Muc4 Expression ◽  
Children’S Hospital ◽  
Expression Score ◽  
Sensitive Marker

Background: Pediatric salivary gland-type neoplasms (SGTNs) pose a significant diagnostic problem due to histo-morphological heterogeneity. Previous reports have shown that Mucin 4 (MUC4) expression is associated with adult mucoepidermoid carcinoma (MEC). We hypothesize that MUC4 is also a sensitive marker for distinguishing MEC from other SGTNs in the pediatric population. Objective: To evaluate MUC4 expression in pediatric SGTNs. Methods: A retrospective review of 74 SGTNs diagnosed between 1993–2015 at Children’s Hospital Los Angeles, Boston Children’s Hospital, and Rhode Island Hospital was performed. H&E sections of 31 MECs were compared to 3 adenoid cystic carcinomas (AdCCs), 6 acinic cell carcinomas (AcCCs), 30 pleomorphic adenomas (PAs), 3 mammary analogue secretory carcinomas (MASCs), and one sialoblastoma (SB). Samples underwent immunohistochemical staining for MUC4, with expression score criteria: 0% positivity = 0, 1-10% = +, 11-50% = ++, 51-90% = +++, >90% = ++++. Results: All MECs were MUC4-positive, with 25 (80.65%) having an expression score ≥ +++. AdCCs and PAs demonstrated no to minimal MUC4-positivity. Subsets of AcCCs and MASCs were unexpectedly MUC4-positive. As a novel marker for pediatric MEC, MUC4’s sensitivity = 100%, specificity = 79.41%, positive predictive value = 75.86%, and negative predictive value = 100%. Conclusion: MUC4 is a sensitive marker for pediatric MEC

scholarly journals Children’s Hospital Los Angeles COVID-19 Analysis Research Database (CARD) - A Resource for Rapid SARS-CoV-2 Genome Identification Using Interactive Online Phylogenetic Tools

2020 ◽  
Author(s):  
Lishuang Shen ◽  
Dennis Maglinte ◽  
Dejerianne Ostrow ◽  
Utsav Pandey ◽  
Moiz Bootwalla ◽  
...  
Keyword(s):  
Los Angeles ◽  
Phylogenetic Trees ◽  
Keyword Search ◽  
Full Length ◽  
Research Database ◽  
Effective Response ◽  
Viral Genomes ◽  
Children's Hospital ◽  
Children’S Hospital ◽  
Advanced Analysis

AbstractEffective response to the Coronavirus Disease 2019 (COVID-19) pandemic requires genomic resources and bioinformatics tools for genomic epidemiology and surveillance studies that involve characterizing full-length viral genomes, identifying origins of infections, determining the relatedness of viral infections, performing phylogenetic analyses, and monitoring the continuous evolution of the SARS-CoV-2 viral genomes. The Children’s Hospital, Los Angeles (CHLA) COVID-19 Analysis Research Database (CARD) (https://covid19.cpmbiodev.net/) is a comprehensive genomic resource that provides access to full-length SARS-CoV-2 viral genomes and associated meta-data for over 30,000 (as of May 20, 2020) isolates collected from global sequencing repositories and the sequencing performed at the Center for Personalized Medicine (CPM) at CHLA. Reference phylogenetic trees of global and USA viral isolates were constructed and are periodically updated using selected high quality SARS-CoV-2 genome sequences. These provide the baseline and analytical context for identifying the origin of a viral infection, as well as the relatedness of SARS-CoV-2 genomes of interest. A web-based and interactive Phylogenetic Tree Browser supports flexible tree manipulation and advanced analysis based on keyword search while highlighting time series animation, as well as subtree export for graphical representation or offline exploration. A Virus Genome Tracker accepts complete or partial SARS-CoV-2 genome sequence, compares it against all available sequences in the database (>30,000 at time of writing), detects and annotates the variants, and places the new viral isolate within the global or USA phylogenetic contexts based upon variant profiles and haplotype comparisons, in a few seconds. The generated analysis can potentially aid in genomic surveillance to trace the transmission of any new infection. Using CHLA CARD, we demonstrate the identification of a candidate outbreak point where 13 of 31 CHLA internal isolates may have originated. We also discovered multiple indels of unknown clinical significance in the orf3a gene, and revealed a number of USA-specific variants and haplotypes.

Sign in / Sign up

Export Citation Format

Share Document